( click to enlarge ) Curis (CRIS) Breakout again !!!! Really Cool !!!!!! Curis shares closed the day gaining more than 19% to a new 52-week high. CRIS has been on one of the most amazing runs of this most recent bull market. Looking at the daily chart the investor sentiment in Curis ...

( click to enlarge ) Curis (CRIS) is trading in a tight range between $2.10 ( 13 dma ) and $2.21 ( 50 dma ). I think the market is waiting for fresh news to define the trend, however if the stock breaks the 50-day moving average , then that is a bullish ...

Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) announced the Company will present at the Lazard Capital Markets 6th Annual Healthcare Conference on Wednesday, November 18th at 3:15 p.m. Eastern time (12:15 p.m. Pacific time) at the St. Regis in New York.Adamis Pharmaceuticals Corporation (OTC:ADMP), announced it’s wholly owned subsidiary, Adamis Labs has now secured distribution contracts and initial stocking orders from the three major wholesalers of prescription drugs in the U.S.Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) announced Dr. Leonard Bell, Chief Executive Officer of Alexion Pharmaceuticals, will present at Lazard Capital Markets 6th Annual Healthcare Conference in New York City at 10:00 a.m. ET on Wednesday, November 18, 2009.

Bruker Corporation (NASDAQ:BRKR) announced it will present at the Lazard Capital Markets 6th Annual Healthcare Conference on Tuesday, November 17, 2009, at 10:55 AM Eastern Standard Time in New York City.

Covidien (NYSE:COV) will present at the Lazard Capital Markets 6th Annual Healthcare Conference in New York on Wednesday, November 18, 2009.

Curis, Inc. (NASDAQ:CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, announced the Company will be presenting at the Lazard Capital Markets 6th Annual Healthcare Conference at 3:45 p.m. EST on November 18, 2009, in New York City.

Enzo Biochem, Inc. (NYSE:ENZ), a leading vertically integrated clinical lab, life sciences and therapeutic biotechnology company, announced Barry Weiner, President, and David Goldberg, Vice President, Corporate Development, will be presenting at the Lazard Capital Markets 6th Annual Healthcare Conference on Tuesday, November 17, 2009 at 3:40 PM at The St. Regis Hotel in New York, N.Y.

IMS Health (NYSE: RX), the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries, announced the upcoming launch of IMS Oncology QuantifierTM, a comprehensive, clinically rich analytical tool that enables the company’s clients to assess treatment opportunities and guide commercial decisions in the $48 billion global oncology market.

ImmunoGen, Inc. (Nasdaq:IMGN), a biotechnology company that develops targeted anticancer products, announced Howard Pien was elected to its Board of Directors at today’s Annual Meeting of Shareholders.

LecTec Corporation (OTC:LECT) announced it has reached a settlement with Endo Pharmaceuticals Inc. on outstanding patent litigation related to LecTec’s U.S. Patent Nos. 5,536,263 and 5,741,510.

MS Health (NYSE:RX), the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries, announced the upcoming launch of IMS Oncology QuantifierTM, a comprehensive, clinically rich analytical tool that enables the company’s clients to assess treatment opportunities and guide commercial decisions in the $48 billion global oncology market.NexMed, Inc. (Nasdaq:NEXM), a developer of innovative transdermal products based on the NexACT® drug delivery technology, announced it raised $750,000 in gross proceeds from the issuance of new convertible notes due December 31, 2011 (the “Notes”), which are secured by a mortgage on NexMed’s facility in East Windsor, New Jersey.

Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that John Trizzino, Senior Vice President, International and Government Alliances, will be presenting at the Influenza Congress USA 2009.

Chief Research Officer Morris S. Whitcup, Ph.D., of ORC Guideline (NASDAQ:IUSA) will present findings of the company’s recent research on the impact of social media on fair balance and pharmaceutical marketing at a Food and Drug Administration (FDA) public hearing later this week.

PPD, Inc. (Nasdaq:PPDI) announced its board of directors declared a cash dividend for the fourth quarter of 2009 under its annual cash dividend policy. The quarterly cash dividend will equal $0.15 per share.

Synta Pharmaceuticals Corp. (NASDAQ:SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, announced the Company will be presenting at the Lazard Capital Markets 6th Annual Healthcare Conference on Wednesday, November 18 at 10:00 a.m. (ET) at the St. Regis New York.Tongjitang Chinese Medicines Company (NYSE: TCM), a leading specialty pharmaceutical company focusing on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine in China, announced it plans to announce its third quarter 2009 financial results before the market opens on Wednesday, November 18, 2009.

 

Below is a selection of small and micro-cap stocks from my Cancer Diagnostic & Therapeutic (Dx/Tx) Micro-Cap Index that are involved in research activities to improve the treatment of brain cancer. In addition, three of the companies profiled below are among 10 stocks in the Mentor Capital Cancer Immunotherapy Index (MNTR.pk).

 

Northwest Biotherapeutics (OTC:NWBO) is developing DCVax-Brain as an experimental autologous (patient-derived) cellular therapy that is designed to create a specific immune response against a patient’s cancer. DCVax-Brain utilizes a patient’s own dendritic cells (DC), and an extract of the patient’s own tumor cells to achieve an immune response.

 

In early April, Ark Therapeutics (PINK:ARKTF) (LON:AKT) announced the first update of results for its Cerepro Phase 3 clinical trial as a novel gene-based medicine for the treatment of operable malignant glioma. The study is being conducted to confirm the safety and efficacy of Cerepro in patients with operable high grade glioma (brain cancer) against current standard treatment options, including (1) surgery and radiotherapy or (2) surgery and radiotherapy followed approximately 40 days post-op by temozolomide.

 

Significance levels associated with the main data have improved in the update analyses and 29 patients have yet to reach a primary endpoint event (versus 53 previously), of which 18 have been treated with Cerepro and 11 received standard of care treatment. Data suggests improved overall survival in patients receiving Cerepro after about 500 days with 56 patients in the trial still alive. A marketing approval application (MAA) in Europe for Cerepro was filed with the EMEA in 4Q08 and an opinion from the CHMP is expected during 4Q09.

 

Cerepro is a novel gene-based product for the treatment of patients with operable high grade glioma and utilizes a well-established adenoviral vector (Ad5) to introduce the gene that causes cells to express a protein called thymidine kinase ("TK"). Following the standard surgery to remove the solid tumor mass, Cerepro is injected through the wall of the cavity left behind by the surgical removal of the solid tumor, into the surrounding healthy brain tissue. In the following days, the healthy cells in the wall of the cavity express TK.

 

Five days after surgery, the drug ganciclovir (GCV) is given to the patient as part of the overall Cerepro treatment regimen. Neither TK nor GCV is individually active but they react together to produce a substance which destroys cells when they try to divide. Since cell division is a key characteristic of cancer and the normal brain cells are not dividing, cells that try to divide to form a new tumor around the site of the removal of the original tumor are targeted for destruction by the Cerepro treatment.

 

Exelixis (NASDAQ:EXEL) is co-developing XL184 (BMS-907351) along with Bristol-Myers (NYSE:BMY). A Phase 2 trial of XL184 in subjects with progressive or recurrent GBM in first or second relapse is ongoing. XL184 inhibits MET, VEGFR2, and RET, which are key drivers of tumor formation, growth, and metastasis. The Company is also co-developing XL765 along with Sanofi-Aventis (NYSE:SNY). XL765 targets both PI3K and mTOR, which are key elements in pathways leading to cell proliferation and is currently being evaluated in a Phase 1b/2 trial in combination with Temodar in GBM patients.

 

ImmunoCellular Therapeutics (OTC:IMUC) is a cancer immunotherapy company that is developing therapeutic and diagnostic product candidates taking aim at the root cause of the disease, cancer stem cells (CSCs), based on two distinct technology platforms - active (cancer vaccines) and passive (monoclonal antibodies or mAbs).

This approach is in the early stages of development, but has the potential to become a paradigm-shifting therapeutic approach to the treatment of cancer. CSCs are resistant to standard treatments such as chemotherapy and radiation, but numerous bio-markers on these cells have been identified which can be used to develop targeted mAbs and CSC immunotherapy products.

 

Although CSCs account for a small proportion of the cells in a given tumor, a growing body of scientific literature suggests CSCs drive the process of tumor growth and recurrence (even after the disease is undetectable and thought to be eradicated). Current therapeutic options such as radiation therapy or chemo target the proliferating cells, which form the bulk of any tumor mass while the CSCs lie dormant and unaffected at the root of the disease. Thus, a non-detectable number of CSCs may persist even after a patient is in remission, leading to the potential for recurrence of the disease.

 

IMUC’s cancer immunotherapy candidate, ICT-121, is expected to begin Phase I/II clinical testing in humans in early 2010 as an off-the-shelf product (i.e. does not require obtaining cells from the patient as part of the manufacturing process). ICT-121 works by eliciting a targeted T cell immune response specific to MHC class I molecules (which are highly specific to CSCs and cancer cells) and CD133+ cells, since CD133 also occurs on normal cells at reduced levels (e.g. 4,500 copies on a normal cell versus 30,000-180,000 copies on a CSC).

 

Blockbuster potential exists for ICT-121 targeting an unmet medical need (brain cancer initially, then pancreatic cancer) and is designed for use in combination with the current standard of care (i.e. surgery, chemo, and radiation therapy) to target residual disease as a paradigm-shifting treatment with the goal of completely eradicating the presence of cancer cells and their future recurrence or spread. IMUC is also developing CSC-targeting mAbs for both therapeutic and diagnostic applications in the treatment of cancer.

 

Celldex Therapeutics (NASDAQ:CLDX) is developing CDX-110 as a cancer immunotherapy product candidate targeting the tumor specific molecule called EGFRvIII, which is a functional variant (tumor-specific) of the epidermal growth factor receptor (EGFR), a protein that has been well validated as a target for cancer therapy (i.e. Erbitux). While originally discovered in GBM, the expression of EGFRvIII has also been observed in various other cancers such as breast, ovarian, metastatic prostate, colorectal, and head & neck cancers.

 

In collaboration with its partner, Pfizer (NYSE:PFE), Celldex is currently performing a Phase 2 study (the “ACT III” study) of CDX-110 in patients with newly diagnosed GBM. Objectives of the study are to investigate the anticancer activity, impact on survival, and safety of CDX-110 when administered during a 12 month course of maintenance temozolomide chemotherapy and then continuing until disease progression. Approximately 60 patients will receive CDX-110 as part of this study.

 

The National Cancer Institute’s (NCI) Division of Cancer Treatment and Diagnosis (DCTD) is currently sponsoring a Phase I clinical trial to evaluate dose and safety of Curis Inc.'s (NASDAQ:CRIS) GDC-0449 in medulloblastoma patients up to 21 years of age, as well as a Phase II trial in adult patients with medulloblastoma (a malignant tumor of the cerebellum that represents the most common brain malignancy in children). GDC-0449 targets the Hedgehog signaling pathway, blocking the activities of cell surface receptors and suppressing signaling pathways, which play an important role in tissue growth and may lead to the uncontrolled proliferation of cells if mutations occur.

 

Peregrine Pharma (NASDAQ:PPHM) is developing Cotara as an experimental treatment for brain cancer that links a radioactive isotope to a targeted monoclonal antibody designed to bind to a specific DNA histone complex that is exposed by dead and dying cells found at the center of solid tumors. This targeting mechanism enables Cotara to bind to dying tumor cells, delivering a radioactive dose to the adjacent living tumor cells and essentially destroying the tumor from the inside out, with minimal radiation exposure to healthy tissue.

 

In addition to an ongoing Phase 2 trial in India, a dosimetry and dose confirmation trial in GBM patients at leading U.S. academic brain cancer centers is nearing completion. Cotara has been granted orphan drug status and fast track designation for the treatment of GBM and anaplastic astrocytoma by the FDA.

 

Arno Therapeutics (OTC:ARNI) is developing its lead clinical compound (AR-67) as a novel, third-generation camptothecin analogue that inhibits Topoisomerase I activity. AR-67 has demonstrated activity and an excellent safety profile in clinical studies as well as improved pharmacokinetic properties when compared to approved second-generation products, including Hycamtin (topotecan) and Camptosar (irinotecan). The Company expects to begin a Phase 2 study during 2009 for AR-67 in the treatment of GBM.

 

YM BioSciences (AMEX:YMI) is evaluating its lead anti-cancer compound nimotuzumab (nimo) (an IgG1, humanized epidermal growth factor or EGFR targeting monoclonal antibody or MAb) in 11 Phase 2 and 3 international trials, including three by YMI and eight by its licensees. Nimo is in the same class as Erbitux (cetuximab), but has a better safety profile since it does not cause the severe (Grade 3 or 4) skin rash associated with these types of treatments. The lack of severe skin rash would otherwise be a clear advantage, but in this case the clinical effectiveness of EGFR inhibitors is thought to be linked with the occurrence of this side effect (see the Company's corporate presentation for more details and images of Grade 3 or 4 rash).

 

The following are expected milestones for nimo clinical data, with the majority representing studies in both children and adults with a variety of brain cancers: (1) nimo post-marketing data 150 patients in epithelial-derived tumors 3Q09; (2) nimo Phase 2 first-line NSCLC in 2010; (3) nimo European final Phase 3 first-line pediatric glioma data in 2010; (4) nimo European Phase 3 first-line adult glioma data in 2010; (5) nimo North American Phase 2 recurrent pediatric glioma data in 2010; (6) nimo esophageal Phase 2 first-line data (Brazil) in 2010; (7) nimo Phase 2 (Japan) recurrent gastric cancer data possibly in 2010; (8) recruitment by Oncoscience AG in nimo Phase 3 trial among newly diagnosed pediatric pontine glioma patients is concluded; and (9) recruitment by Oncoscience AG in a Phase 3 trial for adult GBM grade IV will be completed in 2009.

 

Lixte Biotech (OTC:LIXT) was originally founded as a diagnostics company in 2005 evaluating biomarkers (indicators of disease at the molecular level), but has shifted its focus to cancer drug discovery research that is primarily focused on the development of compounds for malignancies with few effective treatment options - such as certain types of brain cancer (glioblastoma multiforme or GBM, neuroblastoma, and medulloblastoma) and pancreatic cancer.

 

In early July, Lixte announced that the results of studies characterizing the novel and potent anti-cancer activity and mechanism of action of its lead compound (LB-1.2) both alone and in combination with standard chemotherapy drugs were published in a leading scientific journal, the Proceedings of the National Academy of Sciences.  The primary conclusion was that one of the Company's lead compounds appears to inhibit cancer cells by stimulating cancer cells to attempt to grow in the presence of a standard cancer drug and interferes with cancer cell defense mechanisms, with the end result being much greater damage to the cancer than occurs when treatment is limited to the standard anti-cancer drug.

 

The authors of this study concluded that treatment with the Company's compound LB-1.2 may be a general method for enhancing the therapeutic benefit of a number of standard cancer regimens, not limited to the original targets of brain tumors of adults and children. Based on the positive preclinical results for LB-1.2, Lixte believes its lead compounds have the potential to be used in combination with Temodar (for a similar commercial market opportunity) since nearly all patients with GBM relapse regardless of current treatments and the published study results offer a possible explanation for a synergistic mode of action that must be proven in human clinical trials

 

One lead compound (LB-1) is the most advanced in the process and Lixte plans to be ready for IND submission in mid-2010. The other lead compound (LB-2.5), which inhibits cancer cells by a different mode of action compared to LB-1, is anticipated to complete its evaluation by the end of 2010. If the Company is able to achieve a strategic partnership and funding from an established pharmaceutical company to co-develop its compounds, the development process is expected to occur more quickly since these two lead compounds are well characterized with regards to their activity and mechanism of action. The encouraging preclinical results for LB-1.2 as an add-on treatment for brain cancer, the unmet medical needs for effective brain and pancreatic cancer treatments, and the pending patents for Lixte’s lead compound should increase the awareness of the Company’s research and hopefully result in funding to expedite the process.

 

Disclosure: Long IMUC.ob, MNTR.pk

 

{tiny;ARIA;3}ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) will hold a live webcast of its quarterly conference call at 8:30 a.m. (ET) on Thursday, November 5, 2009. Harvey J. Berger, M.D., chairman and chief executive officer, will host the call. Senior management will discuss the Company’s financial results for the nine months ended September 30, 2009, progress toward 2009 key corporate objectives and additional corporate activities.

The live webcast can be accessed by visiting the investor relations section of the Company’s website at http://www.ariad.com/investor. The call can be accessed by dialing 866-783-2146 (domestic) or 857-350-1605 (international) five minutes prior to the start time and providing the passcode 97543712. A replay of the call will be available on the ARIAD website approximately two hours after completion of the call and will be archived for two weeks.

 

{tiny;OSIR;3}Osiris Therapeutics, Inc. (NASDAQ: OSIR) today announced that it will report its financial results for the quarter ended September 30, 2009, on Wednesday, November 4, 2009. C. Randal Mills, Ph.D., President and Chief Executive Officer, and Philip R. Jacoby, Jr., Chief Financial Officer, will provide a company update and discuss results via a webcast and conference call on Wednesday, November 4, 2009 at 9:00 a.m. ET.

To access the webcast, visit the Investor Relations section of the company's website at http://investor.osiris.com/events.cfm. Alternatively, callers may participate in the conference call by dialing (866) 431-2027 (U.S. participants) or (719) 325-2274 (international participants).

A replay of the conference call will be available approximately two hours after the completion of the call through November 18, 2009. Callers can access the replay by dialing (888) 203-1112 (U.S. participants) or (719) 457-0820 (international participants). The audio replay passcode is 6412442. To access a replay of the webcast, visit the Investor Relations section of the company's website at http://investor.osiris.com/events.cfm.

 

{tiny;insm;3}Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, today announced that it will host a conference call on Friday, November 6th, at 8:30 AM ET, to discuss its financial results for the third quarter 2009. Insmed intends to issue its quarterly financial results press release before the market opens on November 6th.

To participate in the live conference call, please dial 800-573-4754 (U.S. callers) or 617-224-4325 (international), and provide passcode 14720373. A live webcast of the call will also be available at http://phx.corporate-ir.net/playerlink.zhtml?c=122332&s=wm&e=2498647. Please allow extra time prior to the webcast to register, download and install any necessary audio software.

The webcast will be archived for 30 days, and a telephone replay of the call will be available for seven days, beginning at 11:30 AM ET on November 6th at 888-286-8010 (U.S. callers) or 617-801-6888 (international), using passcode 92577797.

 

{tiny;CRIS;3}Curis, Inc. (NASDAQ:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today announced that the Company will release its third quarter financial results on Thursday, October 29, 2009 before the market opens. The Company will also hold a conference call on the same day at 9:00 A.M. Eastern time to discuss: (i) its Hedgehog Pathway Inhibitor program under collaboration with Genentech, (ii) its August 2009 license agreement with Debiopharm under which the Company’s Hsp90 inhibitor technologies, including Debio 0932 (formerly CUDC-305), were exclusively licensed, (iii) CUDC-101 and other proprietary targeted cancer programs, (iv) its financial results as of and for the three- and nine-month periods ended September 30, 2009, and (v) additional corporate activities. Daniel Passeri, President and Chief Executive Officer of Curis, will host the call.To access the live conference call, please call (800) 569-2037 from the United States or Canada or (617) 614-2713 from other locations, shortly before 9:00 A.M. EDT. The conference ID number is 77811969. The conference call can also be accessed on the Curis website at www.curis.com in the Investors section. Replay will be available approximately two hours after the completion of the call and through 5:00 P.M. EST, Thursday, November 5, 2009. To access the replay, please call (888) 286-8010 from the United States or Canada or (617) 801-6888 from other locations and reference the conference ID number 60149533.

 

{tiny;IMGN;3}ImmunoGen, Inc. (Nasdaq:IMGN), a biotechnology company that develops targeted anticancer products, today announced that will host a conference call at 4:30 pm ET on Thursday, October 29, 2009 to discuss the Company’s financial results for the three-month period ended September 30, 2009 – the first quarter of ImmunoGen’s 2010 fiscal year. Management also will provide an update on the Company.

To access the live call by phone, dial 913-312-6698. Passcode is 6451192. The call also may be accessed through the Investor Information section of the Company’s website, www.immunogen.com. Following the live webcast, a replay of the call will be available at the same location through November 5, 2009.

 

{tiny;QCOR;3}Questcor Pharmaceuticals, Inc. (Nasdaq:QCOR) today announced that it will release financial results for the third quarter ended September 30, 2009 on Monday, November 2, 2009 after the market close. The Company will host a conference call and webcast on Monday, November 2, 2009 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss the Company's second quarter and current corporate developments. The dial-in number for the conference call is 480-629-9723 for domestic participants and 877-941-2332 for international participants.

A taped replay of the conference call will also be available beginning approximately one hour after the call's conclusion and will be available for seven days. This replay can be accessed by dialing 800-406-7325 for domestic callers and 303-590-3030 for international callers, both using passcode 4169702#. To access the live webcast of the call, go to Questcor Pharmaceuticals' website at www.questcor.com. An archived webcast will also be available at www.questcor.com.

 

{tiny;NSPH;3}Nanosphere, Inc., (Nasdaq:NSPH), which develops, manufactures, and markets advanced molecular diagnostics systems, will report its results for the third quarter of 2009 after market close on Thursday, November 5, 2009. The company will also hold a live investor conference call and webcast at 5:00 P.M., Eastern Time.

The teleconference can be accessed by dialing 888.713.4218 (U.S./Canada) or 617.213.4870 (international), participant code 68742213. The call will also be broadcast live over the Internet and can be accessed by interested parties at the Investor Relations tab on the Nanosphere website: www.nanosphere.us.

Participants may pre-register for the call at: https://www.theconferencingservice.com/prereg/key.process?key=PCA9ULWQT Pre-registrants will be issued a pin number to use when dialing into the live call, which will provide quick access to the conference by bypassing the operator upon connection. For interested individuals unable to join the call or webcast, a replay will be available through November 11, 2009 by dialing 888-286-8010 or for international calls 617-801-6888, pass code 80886974, or on the company's website.

 

{tiny;PDLI;3}PDL BioPharma, Inc. (Nasdaq: PDLI) today announced that the company will hold a conference call and webcast on Wednesday, October 28 at 4:30 p.m. Eastern Time to discuss its financial results for the third quarter of 2009 and provide a business update. The call and webcast will follow the release of the third quarter ended September 30, 2009 financial results after market close.

To access the live conference call via phone, please dial (866) 804-6928 from the United States and Canada or (857) 350-1674 internationally. The conference ID is 28992227. Please dial in approximately ten minutes prior to the start of the call. A telephone replay will be available beginning approximately one hour after the call through November 3, 2009 and may be accessed by dialing (888) 286-8010 from the United States and Canada or (617) 801-6888 internationally. The replay passcode is 78436903.

 

{tiny;IDIX;3}Idenix Pharmaceuticals, Inc., (Nasdaq: IDIX) announced today that it will report its financial results for the third quarter of 2009 on Thursday, October 29, 2009 after U.S. financial markets close.

In conjunction with the issuance of the press release, Idenix management will host a conference call at 4:30 p.m. ET on Thursday, October 29, 2009 to discuss the company's financial results for the third quarter of 2009 and provide an update on the company's discovery and development programs.

To access the call please dial 800-471-3635 U.S./Canada or 706-758-9475 International and enter passcode 37050246 or to listen to a live webcast and view accompanying slides, go to "Calendar of Events" in the Idenix Investor Center at www.idenix.com. A replay of the call will also be available from October 29, 2009, 6:30 p.m. ET until November 11, 2009, 11:59 p.m. ET. To access the replay, please dial 800-642-1687 U.S./Canada or 706-645-9291 International and enter passcode 37050246. An archived webcast will also be available for two weeks after the call on the Idenix website.

 

{tiny;ANDS;3}Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will report third quarter 2009 financial results on Thursday, October 29, 2009, after the U.S. financial markets close.

Anadys will hold a conference call and webcast on Thursday, October 29, 2009 at 5:00 p.m. Eastern Daylight Time to discuss its third quarter 2009 financial results and highlights and to provide an update on the ANA598 program. A live webcast of the call will be available online at www.anadyspharma.com. A telephone replay will also be available approximately one hour after completion of the call. To access the telephone replay, dial 888-286-8010 (domestic) or 617-801-6888 (international), passcode 81828355. The webcast and telephone replay will be available through November 12, 2009.